Here's how NATURE.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

NATURE . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Nature.com Make Money
  6. How Much Does Nature.com Make
  7. Keywords
  8. Topics
  9. Questions
  10. Schema
  11. Social Networks
  12. External Links
  13. Analytics And Tracking
  14. Libraries
  15. Hosting Providers
  16. CDN Services

We are analyzing https://www.nature.com/articles/s41467-021-21168-6.

Title:
Single-cell profiling identifies pre-existing CD19-negative subclones in a B-ALL patient with CD19-negative relapse after CAR-T therapy | Nature Communications
Description:
Chimeric antigen receptor T cell (CAR-T) targeting the CD19 antigen represents an innovative therapeutic approach to improve the outcome of relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). Yet, despite a high initial remission rate, CAR-T therapy ultimately fails for some patients. Notably, around half of relapsing patients develop CD19 negative (CD19neg) B-ALL allowing leukemic cells to evade CD19-targeted therapy. Herein, we investigate leukemic cells of a relapsing B-ALL patient, at two-time points: before (T1) and after (T2) anti-CD19 CAR-T treatment. We show that at T2, the B-ALL relapse is CD19 negative due to the expression of a non-functional CD19 transcript retaining intron 2. Then, using single-cell RNA sequencing (scRNAseq) approach, we demonstrate that CD19neg leukemic cells were present before CAR-T cell therapy and thus that the relapse results from the selection of these rare CD19neg B-ALL clones. In conclusion, our study shows that scRNAseq profiling can reveal pre-existing CD19neg subclones, raising the possibility to assess the risk of targeted therapy failure. CD19-negative relapses are observed in patients with B-cell acute lymphoblastic leukemia (B-ALL) treated with anti-CD19 CAR-T cells. Here, by single-cell RNA sequencing of leukemic cells in a patient with B-ALL, the authors show that pre-existing CD19 negative leukemic subclones are present before CAR-T cell therapy and can account for the relapse.
Website Age:
30 years and 10 months (reg. 1994-08-11).

Matching Content Categories {📚}

  • Science
  • Education
  • Sports

Content Management System {📝}

What CMS is nature.com built with?

Custom-built

No common CMS systems were detected on Nature.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of nature.com audience?

🌆 Monumental Traffic: 20M - 50M visitors per month


Based on our best estimate, this website will receive around 42,554,915 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Nature.com Make Money? {💸}


Display Ads {🎯}


The website utilizes display ads within its content to generate revenue. Check the next section for further revenue estimates.

Ads are managed by yourbow.com. Particular relationships are as follows:

Direct Advertisers (10)
google.com, pmc.com, doceree.com, yourbow.com, audienciad.com, onlinemediasolutions.com, advibe.media, aps.amazon.com, getmediamx.com, onomagic.com

Reseller Advertisers (38)
conversantmedia.com, rubiconproject.com, pubmatic.com, appnexus.com, openx.com, smartadserver.com, lijit.com, sharethrough.com, video.unrulymedia.com, google.com, yahoo.com, triplelift.com, onetag.com, sonobi.com, contextweb.com, 33across.com, indexexchange.com, media.net, themediagrid.com, adform.com, richaudience.com, sovrn.com, improvedigital.com, freewheel.tv, smaato.com, yieldmo.com, amxrtb.com, adyoulike.com, adpone.com, criteo.com, smilewanted.com, 152media.info, e-planning.net, smartyads.com, loopme.com, opera.com, mediafuse.com, betweendigital.com

How Much Does Nature.com Make? {💰}


Display Ads {🎯}

$536,300 per month
According to our algorithms, Nature.com's monthly online income from display advertising ranges from $357,503 to $983,134.

Keywords {🔍}

cells, ball, cell, article, cart, therapy, fig, cdneg, google, scholar, tcdneg, supplementary, nature, expression, analysis, relapse, clusters, cas, data, leukemia, samples, acute, clones, tcdpos, pcr, antigen, lymphoblastic, mrna, singlecell, cancer, patient, leukemic, gene, cdna, genes, scrnaseq, med, chimeric, patients, anticd, treatment, car, tumoral, performed, information, study, genomics, umap, expressed, facs,

Topics {✒️}

org/cistarget/databases/homo_sapiens/hg19/refseq_r45/mc9nr/gene_based/hg19-tss-centered-10kb-7species hg19-tss-centered-10kb-7species nature portfolio org/record/4114854/files/refdata-cellranger-grch38-3 /supp/cell-exp/refdata-cellranger-grch38-3 privacy policy middle facs plots distinct anti-cd45-hashtag oligonucleotide advertising click chemistry tools social media regional council mrna library reads water 10 mm tco-peg4-nhs nature 545 nature specific anti-cd45-hto antibody future research reprints single-cell rna sequencing single-cell rna-sequencing acute lymphoblastic leukaemia libraries sequencing chimeric antigen receptor–modified research design research funding horizon 2020 research b-acute lymphoblastic leukemia bulk rna-sequencing data single-cell cdna synthesis dominique payet-bornet b-cell lymphoblastic leukemia express full-length transcripts 10 mm tco-peg4-nhs cancer-related childhood mortality1 investigate large-scale cnv peer review reports acute lymphoblastic leukemia 1 mm mtz-peg4-nhs evade cd19-targeted therapy cd19-negative relapse permitting de la sant� original author permissions chimeric antigen receptor libraries single-cell data escape car-mediated recognition /hoohm/cite-seq-count chimeric antigen receptors

Questions {❓}

  • Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?
  • Gov/sra?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Single-cell profiling identifies pre-existing CD19-negative subclones in a B-ALL patient with CD19-negative relapse after CAR-T therapy
         description:Chimeric antigen receptor T cell (CAR-T) targeting the CD19 antigen represents an innovative therapeutic approach to improve the outcome of relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). Yet, despite a high initial remission rate, CAR-T therapy ultimately fails for some patients. Notably, around half of relapsing patients develop CD19 negative (CD19neg) B-ALL allowing leukemic cells to evade CD19-targeted therapy. Herein, we investigate leukemic cells of a relapsing B-ALL patient, at two-time points: before (T1) and after (T2) anti-CD19 CAR-T treatment. We show that at T2, the B-ALL relapse is CD19 negative due to the expression of a non-functional CD19 transcript retaining intron 2. Then, using single-cell RNA sequencing (scRNAseq) approach, we demonstrate that CD19neg leukemic cells were present before CAR-T cell therapy and thus that the relapse results from the selection of these rare CD19neg B-ALL clones. In conclusion, our study shows that scRNAseq profiling can reveal pre-existing CD19neg subclones, raising the possibility to assess the risk of targeted therapy failure. CD19-negative relapses are observed in patients with B-cell acute lymphoblastic leukemia (B-ALL) treated with anti-CD19 CAR-T cells. Here, by single-cell RNA sequencing of leukemic cells in a patient with B-ALL, the authors show that pre-existing CD19 negative leukemic subclones are present before CAR-T cell therapy and can account for the relapse.
         datePublished:2021-02-08T00:00:00Z
         dateModified:2021-02-08T00:00:00Z
         pageStart:1
         pageEnd:7
         license:http://creativecommons.org/licenses/by/4.0/
         sameAs:https://doi.org/10.1038/s41467-021-21168-6
         keywords:
            Acute lymphocytic leukaemia
            Cancer immunotherapy
            Science
            Humanities and Social Sciences
            multidisciplinary
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41467-021-21168-6/MediaObjects/41467_2021_21168_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41467-021-21168-6/MediaObjects/41467_2021_21168_Fig2_HTML.png
         isPartOf:
            name:Nature Communications
            issn:
               2041-1723
            volumeNumber:12
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Nature Publishing Group UK
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Tracy Rabilloud
               affiliation:
                     name:CIML
                     address:
                        name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Delphine Potier
               url:http://orcid.org/0000-0003-1684-9888
               affiliation:
                     name:CIML
                     address:
                        name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Saran Pankaew
               affiliation:
                     name:CIML
                     address:
                        name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Mathis Nozais
               url:http://orcid.org/0000-0001-8114-904X
               affiliation:
                     name:CIML
                     address:
                        name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Marie Loosveld
               url:http://orcid.org/0000-0002-8372-4148
               affiliation:
                     name:CIML
                     address:
                        name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
                        type:PostalAddress
                     type:Organization
                     name:Laboratoire d’Hématologie
                     address:
                        name:APHM, Hôpital La Timone, Laboratoire d’Hématologie, Marseille, France
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Dominique Payet-Bornet
               url:http://orcid.org/0000-0003-3196-3814
               affiliation:
                     name:CIML
                     address:
                        name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Single-cell profiling identifies pre-existing CD19-negative subclones in a B-ALL patient with CD19-negative relapse after CAR-T therapy
      description:Chimeric antigen receptor T cell (CAR-T) targeting the CD19 antigen represents an innovative therapeutic approach to improve the outcome of relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). Yet, despite a high initial remission rate, CAR-T therapy ultimately fails for some patients. Notably, around half of relapsing patients develop CD19 negative (CD19neg) B-ALL allowing leukemic cells to evade CD19-targeted therapy. Herein, we investigate leukemic cells of a relapsing B-ALL patient, at two-time points: before (T1) and after (T2) anti-CD19 CAR-T treatment. We show that at T2, the B-ALL relapse is CD19 negative due to the expression of a non-functional CD19 transcript retaining intron 2. Then, using single-cell RNA sequencing (scRNAseq) approach, we demonstrate that CD19neg leukemic cells were present before CAR-T cell therapy and thus that the relapse results from the selection of these rare CD19neg B-ALL clones. In conclusion, our study shows that scRNAseq profiling can reveal pre-existing CD19neg subclones, raising the possibility to assess the risk of targeted therapy failure. CD19-negative relapses are observed in patients with B-cell acute lymphoblastic leukemia (B-ALL) treated with anti-CD19 CAR-T cells. Here, by single-cell RNA sequencing of leukemic cells in a patient with B-ALL, the authors show that pre-existing CD19 negative leukemic subclones are present before CAR-T cell therapy and can account for the relapse.
      datePublished:2021-02-08T00:00:00Z
      dateModified:2021-02-08T00:00:00Z
      pageStart:1
      pageEnd:7
      license:http://creativecommons.org/licenses/by/4.0/
      sameAs:https://doi.org/10.1038/s41467-021-21168-6
      keywords:
         Acute lymphocytic leukaemia
         Cancer immunotherapy
         Science
         Humanities and Social Sciences
         multidisciplinary
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41467-021-21168-6/MediaObjects/41467_2021_21168_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41467-021-21168-6/MediaObjects/41467_2021_21168_Fig2_HTML.png
      isPartOf:
         name:Nature Communications
         issn:
            2041-1723
         volumeNumber:12
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Nature Publishing Group UK
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Tracy Rabilloud
            affiliation:
                  name:CIML
                  address:
                     name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Delphine Potier
            url:http://orcid.org/0000-0003-1684-9888
            affiliation:
                  name:CIML
                  address:
                     name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Saran Pankaew
            affiliation:
                  name:CIML
                  address:
                     name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Mathis Nozais
            url:http://orcid.org/0000-0001-8114-904X
            affiliation:
                  name:CIML
                  address:
                     name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Marie Loosveld
            url:http://orcid.org/0000-0002-8372-4148
            affiliation:
                  name:CIML
                  address:
                     name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
                     type:PostalAddress
                  type:Organization
                  name:Laboratoire d’Hématologie
                  address:
                     name:APHM, Hôpital La Timone, Laboratoire d’Hématologie, Marseille, France
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Dominique Payet-Bornet
            url:http://orcid.org/0000-0003-3196-3814
            affiliation:
                  name:CIML
                  address:
                     name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Nature Communications
      issn:
         2041-1723
      volumeNumber:12
Organization:
      name:Nature Publishing Group UK
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:CIML
      address:
         name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
         type:PostalAddress
      name:CIML
      address:
         name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
         type:PostalAddress
      name:CIML
      address:
         name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
         type:PostalAddress
      name:CIML
      address:
         name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
         type:PostalAddress
      name:CIML
      address:
         name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
         type:PostalAddress
      name:Laboratoire d’Hématologie
      address:
         name:APHM, Hôpital La Timone, Laboratoire d’Hématologie, Marseille, France
         type:PostalAddress
      name:CIML
      address:
         name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Tracy Rabilloud
      affiliation:
            name:CIML
            address:
               name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
               type:PostalAddress
            type:Organization
      name:Delphine Potier
      url:http://orcid.org/0000-0003-1684-9888
      affiliation:
            name:CIML
            address:
               name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
               type:PostalAddress
            type:Organization
      name:Saran Pankaew
      affiliation:
            name:CIML
            address:
               name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
               type:PostalAddress
            type:Organization
      name:Mathis Nozais
      url:http://orcid.org/0000-0001-8114-904X
      affiliation:
            name:CIML
            address:
               name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
               type:PostalAddress
            type:Organization
      name:Marie Loosveld
      url:http://orcid.org/0000-0002-8372-4148
      affiliation:
            name:CIML
            address:
               name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
               type:PostalAddress
            type:Organization
            name:Laboratoire d’Hématologie
            address:
               name:APHM, Hôpital La Timone, Laboratoire d’Hématologie, Marseille, France
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Dominique Payet-Bornet
      url:http://orcid.org/0000-0003-3196-3814
      affiliation:
            name:CIML
            address:
               name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
      name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
      name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
      name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
      name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
      name:APHM, Hôpital La Timone, Laboratoire d’Hématologie, Marseille, France
      name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France

External Links {🔗}(101)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Prism.js
  • Zoom.js

Emails and Hosting {✉️}

Mail Servers:

  • mxa-002c5801.gslb.pphosted.com
  • mxb-002c5801.gslb.pphosted.com

Name Servers:

  • pdns1.ultradns.net
  • pdns2.ultradns.net
  • pdns3.ultradns.org
  • pdns4.ultradns.org
  • pdns5.ultradns.info
  • pdns6.ultradns.co.uk

CDN Services {📦}

  • Crossref

5.19s.